Pharmacokinetics of isradipine in patien
β
J. Cotting; J. Reichen; K. Kutz; R. Laplanche; E. NΓΌesch
π
Article
π
1990
π
Springer
π
English
β 523 KB
The pharmacokinetics of the dihydropyridine calcium antagonist isradipine has been examined in 8 healthy volunteers, 7 patients with non-cirrhotic chronic liver disease (CLD), and 8 patients with biopsy-proven cirrhosis (CIR). Isradipine was simultaneously given orally (12C 5 mg) and i.v. (13C 1 mg)